Genetics and genomics of Parkinson’s disease

Abstract

Parkinson's disease (PD) is a progressively debilitating neurodegenerative syndrome. Although best described as a movement disorder, the condition has prominent autonomic, cognitive, psychiatric, sensory and sleep components. Striatal dopaminergic innervation and nigral neurons are progressively lost, with associated Lewy pathology readily apparent on autopsy. Nevertheless, knowledge of the molecular events leading to this pathophysiology is limited. Current therapies offer symptomatic benefit but they fail to slow progression and patients continue to deteriorate. Recent discoveries in sporadic, Mendelian and more complex forms of parkinsonism provide novel insight into disease etiology; 28 genes, including those encoding alpha-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2) and microtubule-associated protein tau (MAPT), have been linked and/or associated with PD. A consensus regarding the affected biological pathways and molecular processes has also started to emerge. In early-onset and more a typical PD, deficits in mitophagy pathways and lysosomal function appear to be prominent. By contrast, in more typical late-onset PD, chronic, albeit subtle, dysfunction in synaptic transmission, early endosomal trafficking and receptor recycling, as well as chaperone-mediated autophagy, provide a unifying synthesis of the molecular pathways involved. Disease-modification (neuroprotection) is no longer such an elusive goal given the unparalleled opportunity for diagnosis, translational neuroscience and therapeutic development provided by genetic discovery.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 153

1. 1.

   de Lau LM Breteler MM Epidemiology of Parkinson’s diseaseLancet Neurol2006 5525535

   Not in our library10.1016/s1474-4422(06)70471-9

2. 2.

   Fahn S Description of Parkinson’s disease as a clinical syndromeAnn N Y Acad Sci2003 991114

   Not in our library10.1111/j.1749-6632.2003.tb07458.x

3. 3.

   Benabid AL Chabardes S Mitrofanis J Pollak P Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s diseaseLancet Neurol2009 86781

   Not in our library10.1016/s1474-4422(08)70291-6

4. 4.

   Langston JW The Parkinson’s complex: parkinsonism is just the tip of the icebergAnn Neurol2006 59591596

   Not in our library10.1002/ana.20834

5. 5.

   Aarsland D Kurz MW The epidemiology of dementia associated with Parkinson’s diseaseBrain Pathol2010 20633639

   Not in our library10.1111/j.1750-3639.2009.00369.x

6. 6.

   Hughes AJ Daniel SE Ben-Shlomo Y Lees AJ The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder serviceBrain2002 125861870

   Not in our library10.1093/brain/awf080

7. 7.

   Goedert M Spillantini MG Del Tredici K Braak H 100 years of Lewy pathologyNat Rev Neurol2013 91324

   Not in our library10.1038/nrneurol.2012.242

8. 8.

   Trinh J Farrer M Advances in the genetics of Parkinson diseaseNat Rev Neurol2013 9445454

   Not in our library10.1038/nrneurol.2013.132

9. 9.
   Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease · 2011

   No notice
10. 10.

    Wirdefeldt K Gatz M Reynolds CA Prescott CA Pedersen NL Heritability of Parkinson disease in Swedish twins: a longitudinal studyNeurobiol Aging1923 2011e1e8

    Not in our library10.1016/j.neurobiolaging.2011.02.017

11. 11.

    Ross OA Braithwaite AT Skipper LM Kachergus J Hulihan MM Middleton FA Nishioka K Fuchs J Gasser T Maraganore DM Adler CH Larvor L Chartier-Harlin MC Nilsson C Langston JW Gwinn K Hattori N Farrer MJ Genomic investigation of alpha-synuclein multiplication and parkinsonismAnn Neurol2008 63743750

    Not in our library10.1002/ana.21380

12. 12.

    Abeliovich A Schmitz Y Farinas I Choi-Lundberg D Ho WH Castillo PE Shinsky N Verdugo JM Armanini M Ryan A Hynes M Phillips H Sulzer D Rosenthal A Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine systemNeuron2000 25239252

    Not in our library10.1016/s0896-6273(00)80886-7

13. 13.

    Burre J Sharma M Tsetsenis T Buchman V Etherton MR Sudhof TC Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitroScience2010 32916631667

    Not in our library10.1126/science.1195227

14. 14.

    Olanow CW Prusiner SB Is Parkinson’s disease a prion disorder?Proc Natl Acad Sci U S A2009 1061257112572

    Not in our library10.1073/pnas.0906759106

15. 15.

    Kordower JH Chu Y Hauser RA Freeman TB Olanow CW Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s diseaseNat Med2008 14504506

    Not in our library10.1038/nm1747

16. 16.

    Luk KC Kehm V Carroll J Zhang B O’Brien P Trojanowski JQ Lee VM Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic miceScience2012 338949953

    Not in our library10.1126/science.1227157

17. 17.
    α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra · 2010

    No notice
18. 18.

    Valera E Masliah E Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathiesPharmacol Ther2013 138311322

    Not in our library10.1016/j.pharmthera.2013.01.013

19. 19.

    Trinh J Amouri R Duda JE Morley JF Read M Donald A Vilarino-Guell C Thompson C Szu Tu C Gustavsson EK Ben Sassi S Hentati E Zouari M Farhat E Nabli F Hentati F Farrer MJ A comparative study of Parkinson’s disease and leucine-rich repeat kinase 2 p.G2019S parkinsonismNeurobiol Aging2014 3511251131

    Not in our library10.1016/j.neurobiolaging.2013.11.015

20. 20.

    Ozelius LJ Senthil G Saunders-Pullman R Ohmann E Deligtisch A Tagliati M Hunt AL Klein C Henick B Hailpern SM Lipton RB Soto-Valencia J Risch N Bressman SB LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi JewsN Engl J Med2006 354424425

    Not in our library10.1056/nejmc055509

21. 21.

    Clark LN Wang Y Karlins E Saito L Mejia-Santana H Harris J Louis ED Cote LJ Andrews H Fahn S Waters C Ford B Frucht S Ottman R Marder K Frequency of LRRK2 mutations in early- and late-onset Parkinson diseaseNeurology2006 6717861791

    Not in our library10.1212/01.wnl.0000244345.49809.36

22. 22.

    Hentati F Trinh J Thompson C Nosova E Farrer MJ Aasly JO LRRK2 parkinsonism in Tunisia and Norway: a comparative study of disease penetranceNeurology2014 8312

    Not in our library10.1212/wnl.0000000000000675

23. 23.

    Hulihan MM Ishihara-Paul L Kachergus J Warren L Amouri R Elango R Prinjha RK Upmanyu R Kefi M Zouari M Sassi SB Yahmed SB El Euch-Fayeche G Matthews PM Middleton LT Gibson RA Hentati F Farrer MJ LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic studyLancet Neurol2008 7591594

    Not in our library10.1016/s1474-4422(08)70116-9

24. 24.

    Thaler A Ash E Gan-Or Z Orr-Urtreger A Giladi N The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi JewsJ Neural Transm2009 11614731482

    Not in our library10.1007/s00702-009-0303-0

25. 25.

    Gardet A Benita Y Li C Sands BE Ballester I Stevens C Korzenik JR Rioux JD Daly MJ Xavier RJ Podolsky DK LRRK2 is involved in the IFN-gamma response and host response to pathogensJ Immunol2010 18555775585

    Not in our library10.4049/jimmunol.1000548

26. 26.

    Herzig MC Kolly C Persohn E Theil D Schweizer T Hafner T Stemmelen C Troxler TJ Schmid P Danner S Schnell CR Mueller M Kinzel B Grevot A Bolognani F Stirn M Kuhn RR Kaupmann K van der Putten PH Rovelli G Shimshek DR LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in miceHum Mol Genet2011 2042094223

    Not in our library10.1093/hmg/ddr348

27. 27.

    Umeno J Asano K Matsushita T Matsumoto T Kiyohara Y Iida M Nakamura Y Kamatani N Kubo M Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn’s disease and ulcerative colitisInflamm Bowel Dis2011 1724072415

    Not in our library10.1002/ibd.21651

28. 28.

    Funayama M Li Y Tomiyama H Yoshino H Imamichi Y Yamamoto M Murata M Toda T Mizuno Y Hattori N Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian populationNeuroreport2007 18273275

    Not in our library10.1097/wnr.0b013e32801254b6

29. 29.

    Ross OA Toft M Whittle AJ Johnson JL Papapetropoulos S Mash DC Litvan I Gordon MF Wszolek ZK Farrer MJ Dickson DW Lrrk2 and Lewy body diseaseAnn Neurol2006 59388393

    Not in our library10.1002/ana.20731

30. 30.

    Rajput A Dickson DW Robinson CA Ross OA Dachsel JC Lincoln SJ Cobb SA Rajput ML Farrer MJ Parkinsonism, Lrrk2 G2019S, and tau neuropathologyNeurology2006 6715061508

    Not in our library10.1212/01.wnl.0000240220.33950.0c

31. 31.

    Ujiie S Hatano T Kubo S Imai S Sato S Uchihara T Yagishita S Hasegawa K Kowa H Sakai F Hattori N LRRK2 I2020T mutation is associated with tau pathologyParkinsonism Relat Disord2012 18819823

    Not in our library10.1016/j.parkreldis.2012.03.024

32. 32.

    Zimprich A Biskup S Leitner P Lichtner P Farrer M Lincoln S Kachergus J Hulihan M Uitti RJ Calne DB Stoessl AJ Pfeiffer RF Patenge N Carbajal IC Vieregge P Asmus F Müller-Myhsok B Dickson DW Meitinger T Strom TM Wszolek ZK Gasser T Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathologyNeuron2004 44601607

    Not in our library10.1016/j.neuron.2004.11.005

33. 33.

    Marin I van Egmond WN van Haastert PJ The Roco protein family: a functional perspectiveFASEB J2008 2231033110

    Not in our library10.1096/fj.08-111310

34. 34.

    Ross OA Soto-Ortolaza AI Heckman MG Aasly JO Abahuni N Annesi G Bacon JA Bardien S Bozi M Brice A Brighina L Van Broeckhoven C Carr J Chartier-Harlin MC Dardiotis E Dickson DW Diehl NN Elbaz A Ferrarese C Ferraris A Fiske B Gibson JM Gibson R Hadjigeorgiou GM Hattori N Ioannidis JP Jasinska-Myga B Jeon BS Kim YJ Klein C Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control studyLancet Neurol2011 10898908

    Not in our library10.1016/s1474-4422(11)70175-2

35. 35.

    West AB Moore DJ Biskup S Bugayenko A Smith WW Ross CA Dawson VL Dawson TM Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityProc Natl Acad Sci U S A2005 1021684216847

    Not in our library10.1073/pnas.0507360102

36. 36.

    Jaleel M Nichols RJ Deak M Campbell DG Gillardon F Knebel A Alessi DR LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activityBiochem J2007 405307317

    Not in our library10.1042/bj20070209

37. 37.
    Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization · 2010

    No notice
38. 38.

    Deng X Dzamko N Prescott A Davies P Liu Q Yang Q Lee JD Patricelli MP Nomanbhoy TK Alessi DR Gray NS Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2Nat Chem Biol2011 7203205

    Not in our library10.1038/nchembio.538

39. 39.

    Gilsbach BK Kortholt A Structural biology of the LRRK2 GTPase and kinase domains: implications for regulationFront Mol Neurosci2014 732

    Not in our library10.3389/fnmol.2014.00032

40. 40.

    de Silva R Hardy J Crook J Khan N Graham EA Morris CM Wood NW Lees AJ The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson’s diseaseNeurosci Lett2002 330201203

    Not in our library10.1016/s0304-3940(02)00742-5

Cited by papers we hold 4

• NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease · 2018
  No notice
• ER–mitochondria signaling in Parkinson’s disease · 2018
  No notice
• Advances in the delivery of RNA therapeutics: from concept to clinical reality · 2017
  No notice
• The role of Ca2+ signaling in Parkinson's disease · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.